Helix Bio builds sequence-specific oligonucleotide and gene therapies that recognize a target, copy intent, and express the protein a patient is missing, all read to single-base precision.
Four therapeutic modalities. Thirty-eight validated targets. Eleven programs now in the clinic, each one traced back to a single base that was out of place.
A guide strand walks the genome and docks onto its complementary motif. Watson and Crick pairing is read base by base, so affinity is sequence-specific: a single mismatch reads differently from a perfect site.
Helicase peels the duplex apart; polymerase reads each parent strand and lays down a faithful copy while the cell commits to division. What morphs on screen is replication caught in place, order copying itself forward through living matter.
Ribosomes translate the corrected transcript into working protein. The dose restores biology that was missing, then clears: measured, transient, reversible by design.
© 2024 Helix Bio Therapeutics · All sequences reserved